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A challenge in the treatment of Staphylococcus aureus infections is the high prevalence of methicillin-resistant S. aureus (MRSA) strains and the formation of non-growing, dormant 'persister' subpopulations that exhibit high levels of tolerance to antibiotics [1] [2] [3] and have a role in chronic or recurrent infections 4, 5 . As conventional antibiotics are not effective in the treatment of infections caused by such bacteria, novel antibacterial therapeutics are urgently required. Here we used a Caenorhabditis elegans-MRSA infection screen 6 to identify two synthetic retinoids, CD437 and CD1530, which kill both growing and persister MRSA cells by disrupting lipid bilayers. CD437 and CD1530 exhibit high killing rates, synergism with gentamicin, and a low probability of resistance selection. All-atom molecular dynamics simulations demonstrated that the ability of retinoids to penetrate and embed in lipid bilayers correlates with their bactericidal ability. An analogue of CD437 was found to retain anti-persister activity and show an improved cytotoxicity profile. Both CD437 and this analogue, alone or in combination with gentamicin, exhibit considerable efficacy in a mouse model of chronic MRSA infection. With further development and optimization, synthetic retinoids have the potential to become a new class of antimicrobials for the treatment of Gram-positive bacterial infections that are currently difficult to cure.
We used an established automated high-throughput C. elegans-MRSA killing assay in 384-well plates 6 to screen approximately 82,000 small synthetic molecules, and identified 185 compounds that significantly decreased the ability of MRSA to kill the nematodes (Fig. 1a , Supplementary Table 1, Supplementary Methods). Two of these 185 compounds, the synthetic retinoids CD437 and CD1530 (vitamin A analogues; Fig. 1b) , were selected for further investigation because they have similar structures and have been studied previously for their therapeutic potential [7] [8] [9] [10] . CD437 and CD1530 exhibit potent in vitro bactericidal activity against MRSA strain MW2; after two hours, levels of MW2 were below the limit of detection (minimum inhibitory concentration (MIC) 1 μg ml Table 2 ). In vivo, CD437 or CD1530 at concentrations above their in vitro MICs protected 100% of C. elegans against MW2-induced death (Fig. 1d ). CD437 and CD1530 also exhibited potent activity against a panel of clinical S. aureus and Enterococcus faecium strains, but not against Gram-negative species (Supplementary Table 2 ). In addition, adarotene, a structural analogue of CD437 and CD1530 and a potential ovarian cancer drug 8 ( Fig. 1b) , also exhibited significant anti-staphylococcal activity (MIC 2 μg ml −1 ) and prevented the MRSA-induced death of C. elegans. However, adapalene, another analogue and a US Food and Drug Administration (FDA)-approved acne therapeutic 11 , was ineffective against MRSA ( Fig. 1a-d Table 2) .
We were unable to obtain retinoid-resistant mutants by plating 10 10 colony-forming units (CFU) of S. aureus MW2 on agar containing 2.5×, 5× or 10× MIC of CD437, CD1530 or adarotene. Similarly, serial passage of two independent S. aureus MW2 cultures (SP1 and SP2) for 100 days in sub-MIC levels of CD437 yielded only putative mutants with twofold greater resistance to CD437, CD1530 or adarotene, whereas serial passage in ciprofloxacin for 100 days (Fig. 1e ) or daptomycin for 15 days (Extended Data Fig. 1b ) generated strains that were 256-fold and tenfold more resistant, respectively. The MW2 cultures that exhibited modest retinoid resistance contained mutations in the genes graS, yjbH and manA (Fig. 1f, Supplementary Tables 3-5 , Supplementary Discussion), which encode products related to membrane physiology [12] [13] [14] [15] [16] . Consistent with this finding, CD437, CD1530 and adarotene-but not adapalene-induced membrane permeabilization in MW2 (monitored by SYTOX Green uptake; Fig. 2a) , and CD437 and CD1530 caused the formation of mesosome-like structures (observed by transmission electron microscopy; Fig. 2b ), similar to those observed in S. aureus cells after treatment with antimicrobial peptides 17 . Moreover, CD437, CD1530 and adarotene disrupted the integrity of biomembrane-mimicking giant unilamellar vesicles (Fig. 2c , Supplementary Videos 1-5). These vesicles consist of a DOPC:DOPG lipid bilayer at a ratio of 7:3 (DOPC/G, 1,2-dioleoyl-sn-glycero-3-phosphocholine/glycerol), which mimics anionic bacterial membranes, and have been used to elucidate the mechanisms of action of daptomycin in S. aureus 18, 19 . Notably, however, CD437 and CD1530 did not lyse bacterial cells directly (Extended Data Fig. 1c) .
To elucidate the molecular interactions between retinoids and the membrane lipid bilayers of S. aureus, we conducted all-atom molecular dynamics simulations using a lipid bilayer composed of 108 phosphatidylglycerol lipids, 72 lysyl-phosphatidylglycerol (Lys-PG) lipids and 10 diphosphatidylglycerol (DPG, also known as cardiolipin) lipids, which mimics the phospholipid composition of S. aureus membranes 20 . These simulations showed that the carboxylic acid and the phenolic groups of CD437, CD1530 and adarotene anchor these retinoids to the surface of the membrane bilayer by binding persistently to hydrophilic lipid heads. As a result, the retinoids penetrate the bilayers and become embedded orthogonally to the lipid molecules in the outer membrane leaflet, inducing substantial perturbations of the membrane (Fig. 2d , e, Supplementary Videos 6-9). Similar results were obtained for molecular dynamics simulations of DOPC:DOPG (7:3) lipid bilayers used in the giant unilamellar vesicle experiments in Fig. 2c (Extended Data  Fig. 2a , b, Supplementary Videos 10-13). In contrast to CD437, CD1530 and adarotene, adapalene does not penetrate the membrane owing to a high energy barrier (11.22 k B T) and an unfavourable transfer energy (3.16 k B T) (Fig. 2e, Supplementary Table 6 ), as the hydrophobic methoxy group does not bind to lipid heads (Fig. 2d , Supplementary Video 9). CD437-like retinoids can be metabolized in the liver by glucuronidation at carboxylic or hydroxyl groups 21 . Molecular dynamics simulations showed that two CD437 glucuronide metabolites also penetrate into lipid bilayers, exhibiting a similar penetration mechanism to that of CD437 (Extended Data Fig. 2a , c, Supplementary Videos 14, 15, Supplementary Discussion). In summary, these molecular dynamics simulations showed that two polar branch groups-a phenol and a carboxylate-have essential roles in membrane attachment and penetration, and that the membrane acti vity of retinoids (Fig. 2) directly correlates with their antibiotic activity (Fig. 1c, Extended Data Fig. 1a) .
CD437 or CD1530-but not adarotene-also induced rapid permeabilization of MRSA-persister membranes (Extended Data Fig. 3a) , and killed MRSA-persister cells (Fig. 3a, Extended Data Fig. 3b ). They also completely eradicated persisters formed by 13 clinical isolates, including the multi-drug resistant strain VRS1 within 1 to 4 hours at 8-10× MIC (Fig. 3b, Extended Data Fig. 3c, d ). Moreover, CD437 or CD1530 killed around 90% and 100% of persisters formed in MRSA biofilms at 16× MIC and 32× MIC, respectively (Extended Data Fig. 4 ). Compared with adarotene, CD437 and CD1530 can penetrate the membrane more efficiently owing to lower energy barriers and more favourable transfer energies (Fig. 2e) ; this is consistent with the observation that adarotene is inactive against persister cells. The results suggest that the planar aryl moiety of CD437 and CD1530 (highlighted in blue, Fig. 1b ) rigidifies the carboxylic acid, which facilitates penetration into lipid bilayers, whereas the flexible cinnamoyl moiety of adarotene fails to orient the carboxylate appropriately, thereby decreasing membrane penetration (Fig. 2e) .
CD437 or CD1530 exhibited significant synergism with gentamicin against both MRSA growing and persister cells (Fig. 3c , Supplementary Table 7 , Extended Data Fig. 4 ). This is most probably a consequence of the increased passive diffusion of gentamicin through the bacterial cell membranes that have been physically damaged by the retinoids, which is mechanistically distinct from the observed synergism between gentamicin and ionophores 22 (Extended Data Fig. 5 , Supplementary Discussion).
Although membrane-targeting agents often cause toxicity in mammals 23 , CD437, CD1530 and adarotene are relatively non-toxic, exhibiting median haemolytic concentrations (HC 50 ) of greater than 32 μg ml −1 (Extended Data Fig. 6a ). CD437, CD1530 and adarotene were more toxic to human hepatoma HepG2 cells (median lethal concentration (LC 50 ) 3-5 μg ml −1 ) than to normal human primary hepatocytes (LC 50 ≥ 20 μg ml ), or to primary renal proximal tubule epithelial cells or adult normal human epidermal keratinocytes at 8 μg ml −1 (Extended Data Fig. 6b) , a concentration at which CD437 and CD1530 completely eradicated MRSA persisters (Fig. 3a) . These data are consistent with previous results showing that CD437 exhibits selective toxicity towards cancer cells 10 . None of the three retinoids inhibited the human ether-a-go-go related (hERG) potassium channels that are critical for cardiac action potential repolarization at 25 μM (Extended Data Fig. 6c ) and did not show significant genotoxic potential (Supplementary Table 8 ).
To evaluate the effects of the CD437-like retinoid branch groups on antimicrobial activity and the possibility of further structural elegans treated with DMSO. c, d, Individual data points (n = 3 biologically independent experiments) and mean ± s.d. are shown. e, Appearance of spontaneous CD437-and ciprofloxacin-resistant MW2 mutants over 100 days of serial passage in duplicate (SP1 and SP2) (see Supplementary Methods). f, Appearance of mutations on specific days in the indicated genes in SP1 and SP2 in e (see Supplementary Methods). The modest increase in the MIC of CD437 against MRSA during serial passage was confirmed by remeasuring MICs using three colonies from aliquots of each passage that had been stored at −80 °C. Mutated genes are indicated on the day at which the mutations were first detected.
optimization with respect to antimicrobial and toxicity profiles, we synthesized 16 analogues of CD437 (Extended Data Fig. 7a ). Subsequent analysis of their structure-activity relationships supported the putative mode of action by which the synthetic retinoids disrupt Gram-positive bacterial membranes, and demonstrated that the antimicrobial activity and cytotoxicity of synthetic retinoids can be modulated by the polarity of the branch groups (Extended Data Figs 7-9, Supplementary Videos 16, 17, Supplementary Discussion). In particular, analogue 2, which has a less polar primary alcohol instead of the carboxylic acid group, retained bacterial activity against MRSA persisters (Fig. 4a, b) , but showed significantly less haemolytic activity (HC 50 > 32 μg ml −1 , Extended Data Fig. 8a ) and less cytotoxicity in a panel of human cell lines (LC 50 ≥ 31 μg ml −1 ) than did CD437 (Fig. 4c, Extended Data  Fig. 6b ). Analogue 2 also showed significantly reduced activity towards human hepatoma HepG2 cells, with LC 50 values of >32 μg ml −1 (Fig. 4c) . In addition, molecular dynamics simulations revealed that analogue 2 penetrates membrane lipid bilayers with similar energy profiles to those of CD437 (Extended Data Fig. 8d , e, Supplementary Video 16), further establishing that the extent of membrane penetration inferred from molecular dynamics simulations correlates with antimicrobial activity. In summary, the structure-activity relationships verified that persistent attachment to lipid heads by the two polar branch groups is critical for antimicrobial activity, and that antimicrobial activity and lack of cytotoxicity can be optimized by simple modifications to the polar branch groups. Notably, analogue 2 also exhibited favourable pharmacokinetic profiles after intraperitoneal administration of a single dose of 20 mg kg
, with a maximum plasma concentration of around 10 μg ml −1 and an elimination half-life of 4.5 hours (Extended Data Fig. 8f ). By contrast, adarotene is excreted rapidly 21, 24 . Analogue 2 showed no detectable hepatic or renal toxicity in mice at intraperitoneal doses of up to 80 mg kg −1 (the highest tested dose) every 12 hours for 3 days (Extended Data Fig. 8g) .
Finally, we evaluated the efficacy of both analogue 2 and the combination of analogue 2 and gentamicin in a mouse deep-seated thigh MRSA infection model, which mimics human deep-seated chronic infections Time ( in combination with gentamicin also exhi bited efficacy in the MRSA mouse deep-seated thigh infection model (Extended Data Fig. 10 ). These results suggest that a combination of analogue 2 and gentamicin or CD437 and gentamicin might be an effective strategy to enhance the efficacy and reduce the toxicity of aminogly cosides 25 in the treatment of chronic Gram-positive infections.
Despite the potential advantages of membrane-active antimicrobials such as the retinoids described here-including fast killing, low probability of developing resistance, and anti-persister activitythe major obstacle for developing retinoids as therapeutics is their potential cytotoxicity, which is a matter of considerable debate 23, 26 . Nevertheless, we have identified a specific chemotype of membraneactive synthetic retinoids that are relatively selective for bacte rial membranes and exhibit a high level of activity towards MRSA persister cells; these findings are notable because the development of appropriate antibiotics for persisters is an important unmet need. Although a limited analysis of structure-activity relationships showed that modification of the retinoid branch groups can result in improved cytotoxicity profiles while retaining anti-persister activity, it is important to acknowledge that the long term-potential of further chemical optimization of retinoids to develop non-toxic antimicrobials is currently unknown. However, considering the fact that the bioactivity of retinoids can be improved by modifying both the backbone and branch groups, and that approximately 4,000 retinoid analogues have been synthesized so far 26 , our results warrant further development of synthetic retinoids as potential therapeutics for hard-to-treat infectious diseases caused by antibiotic-resistant or persistent Grampositive pathogens.
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Experimental design 1. Sample size
Describe how sample size was determined.
For deep-seated mouse thigh infection studies, we performed a single-tailed power analysis using an estimated STD from other mouse MRSA infection studies from our lab and from the literature (Conlon et al., 2013, Nature, 503, 365-70). For MTD and PK studies, No statistical methods were used to predetermine samples size.
Data exclusions
Describe any data exclusions.
Two data points in the PK study (ED Fig. 8e ) were excluded as outliers based on Grubb's test. (P<0.05). The two outliers were indicated by asterisks in a source data file (ED Fig. 8 .xlsx).
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
All attempts were reproducible.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
No specific randomization method was applied. However, all groups were checked to ensure no significant difference between groups prior to starting experiments. No preference was given to any treatment group in the order of treatment administration.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
During colony counting for in vivo experiments, all samples were numbered and the counting investigator was blinded to the treatment group numbering system. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
